Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Novo Nordisk inks deal on trial obesity drug worth up to $2bn

(Sharecast News) - Danish drugmaker Novo Nordisk has signed a deal worth up $2bn to develop, make and sell United Laboratories International's weight-loss drug candidate.

Under the deal, Novo will pay China-based United $200m up front with a further $1.8bn if development and sales milestones are met for the drug candidate, known as UBT251.

The treatment, which is in trials at the moment, targets three hormones, compared to Novo's own best-selling drug Wegovy, which targets only one that makes people feel fuller for longer.

United Labs unit will keep the rights for UBT251 in China mainland, the Hong Kong Special Administrative Region, the Macau Special Administrative Region and Taiwan, the company said on Monday.

Share this article

Related Sharecast Articles

RBC Capital upgrades Antofagasta to 'sector perform'
(Sharecast News) - RBC Capital Markets upgraded Antofagasta on Thursday to 'sector perform' from 'underperform' but cut the price target to 1,700p from 1,800p.
Poland's InPost to buy Yodel in £106m deal
(Sharecast News) - Poland's InPost said on Thursday that it has bought Yodel, one of the UK's largest parcel delivery companies, in a £106m deal.
BHP delivers record output but warns of 'significant' tariff impact
(Sharecast News) - Mining giant BHP reported record iron ore and copper production across the first nine months of its financial year, but warned of the impact that a trade war could have on demand.
Harmony board drops Drax bid in favour of Foresight offer
(Sharecast News) - Harmony Energy Income Trust (HEIT) announced on Thursday that it has agreed to a recommended cash acquisition by PP Bidco, a company indirectly controlled by funds managed by Foresight Group.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.